Skip to main content

Table 1 Patient characteristics at baseline, N = 53

From: Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study

Patient characteristic

Median (IQR) or n (%)

Age, years

49.0 (38.0–55.0)

Female, n

41.0 (77.4%)

Last known EDSS scorea

2.0 (1.5–3.3)

Time since diagnosis, yearsb

6.5 (3.0–12.0)

Duration of therapy, monthsc

47.0 (30.8–96.3)

Duration of therapy with sc IFN β-1a, months

24.0 (20.0–36.0)

Patients with relapse during past 9 months, n

8.0 (15.1%)

  1. EDSS expanded disability status scale, IFN interferon, IQR interquartile range expressed as Q1–Q3, sc subcutaneous
  2. aData missing for 2 patients
  3. bData missing for 1 patient
  4. cData missing for 5 patients